TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21084077
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine awareness and intention to become vaccinated
Study: 21084077
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of HPV vaccine by ethnicity
Study: 18689368
Drug: Dextrose plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose plus 2.4 g amino acids . kg(‐1) . d(‐1)
Study: 15714185
Drug: 0.2% ropivacaine/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine/0.5 mg mL(‐1) sufentanil
Study: 10226122
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with thermal balloon ablation (single intramuscular administration of GnRH analog)
Study: 10226122
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with thermal balloon ablation (without uterine preparation)
Study: 1881743
Drug: Subcutaneous varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous varicella vaccine
Study: 1881743
Drug: Intramuscular varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular varicella vaccine
Study: 1881743
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes (subcutaneous and intramuscular)
Study: 26037514
Drug: Premeal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premeal insulin injection before a high-carbohydrate meal
Study: 26037514
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal with premeal saline injection
Study: 24432671
Drug: Xiaoyan Zhitong
Normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyan Zhitong Paste (XZP), applied externally, one to two pastes each time, exchanged once per 24 hours, for a total of two 7-day treatment courses.
Study: 19922896
Drug: Combined fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fixed-dose formulation of ticlopidine 250 mg/ginkgo extract 80 mg
Study: 19922896
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of ticlopidine 250 mg and ginkgo extract 80 mg
Study: 11600101
Drug: Subgroup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup of patients hospitalized for less than 2 months after antipsychotic medications were restored
Study: 10423601
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg once daily
Study: 10423601
Drug: Moexipril 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 30 mg once daily
Study: 10423601
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg + Hydrochlorothiazide 25 mg
Study: 10423601
Drug: Moexipril 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 30 mg + Hydrochlorothiazide 50 mg
Study: 7884791
Drug: Moexipril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril monotherapy
Study: 10423601
Drug: Diuretic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic or combination treatment
Study: 3359909
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat (Intralipid 10%)
Study: 3359909
Drug: Intraduodenal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal fat plus cholestyramine (20 g)
Study: 3359909
Drug: All fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All fat infusion groups (Intravenous and Intraduodenal)
Study: 3359909
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat (group IV)
Study: 28215316
Drug: Aronia extract
Normalized name: Aronia melanocarpa fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia extract (500 mg daily)
Study: 12899109
Drug: Indinavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir with nucleoside-analogue reverse-transcriptase inhibitors (NRTI)
Study: 12899109
Drug: NRTI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI monotherapy
Study: 29939894
Drug: Periarticular analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular analgesic injection (PAI)
Study: 26932345
Drug: Golimumab (GOL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (GOL), administered subcutaneously, following a placebo control through weeks 16 and 24.
Study: 22691654
Drug: Oral nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonsteroidal anti‐inflammatory drug (NSAID)
Study: 22691654
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) 10% mannitol and steroid
Study: 22691654
Drug: IV 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 20% mannitol and steroid with oral gabapentin
Study: 18272891
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg intravenous on days 1 and 15)
Study: 16204792
Drug: Intranasal histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal histamine (4 mg/ml, 0.1 ml)
Study: 16204792
Drug: Intranasal histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal histamine
Study: 14576754
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pyridoxine/day
Study: 10665894
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg controlled-release formulation)
Study: 8717596
Drug: TMP-SMX (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMX (160/800 mg) daily
Study: 8717596
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg) monthly
Study: 8390084
Drug: calcium+vitamin D
Normalized name: Calcium/Cholecalciferol 500 MG-10 MCG Oral Tablet [LEADER CALCIUM+VITAMIN D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium+vitamin D supplements
Study: 3443597
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo administration)
Study: 31674093
Drug: Bioengineered bilayered
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioengineered bilayered living cell construct (BLCC) plus compression therapy
Study: 31674093
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (control)
Study: 28574780
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions targeting treatment engagement in youth mental health services
Study: 18568441
Drug: Femal (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femal (160 mg twice-daily for four menstrual cycles)
Study: 12789181
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with Metvix and 75 J/cm² red light, performed twice weekly for 12 weeks, then once weekly.
Study: 12789181
Drug: Paromomycin sulfate,
Normalized name: Paromomycin Sulfate, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin sulfate, administered once daily.
Study: 10619534
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention with counseling to adopt a diet containing 28% or less of calories from total fat, <8% saturated fat, up to 9% polyunsaturated fat, and 11% monounsaturated fat, and dietary cholesterol intake of less than 75 mg/1,000 kcal
Study: 7646090
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm x 10 minutes)
Study: 7646090
Drug: Intravenous prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostacyclin (20 ng.kg‐1.min‐1 x 10 minutes)
Study: 28377389
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus suspension administered orally
Study: 28377389
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus suspension administered via nasogastric tube
Study: 28377389
Drug: Intact capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact capsules
Study: 23955148
Drug: NVS123 formulated
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVS123 formulated as dry filled capsules administered orally with high-fat meal
Study: 23955148
Drug: Alternative formulations
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative formulations developed and assessed in preclinical and/or clinical studies
Study: 23955148
Drug: Amorphous formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous formulation of NVS123
Study: 21563916
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (131I) with an administered activity of 1.85-4.07 MBq per gram of thyroid tissue (average 261 ± 162 MBq) in Group 3
Study: 21563916
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (131I) with varying activities in other groups
Study: 12766641
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg intravenous)
Study: 15504192
Drug: Rocuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.4 mg kg(‐1)
Study: 15504192
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg kg(‐1)
Study: 9061310
Drug: Unheated cornstarch
Normalized name: cornstarch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unheated cornstarch (106 g of CHO)
Study: 9061310
Drug: Mixed equicaloric
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed equicaloric meal (58 g of CHO)
Study: 9061310
Drug: Smaller mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller mixed meal (17 g of CHO)
Study: 2467137
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks
Study: 2467137
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to captopril 25 mg twice daily for 4 weeks
Study: 29775170
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin (INR 2-3)
Study: 23680036
Drug: MIPS (multi-ingredient
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIPS (multi-ingredient performance supplement)
Study: 8971437
Drug: Picotamide (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (900 mg day-1)
Study: 6337405
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of guanabenz twice daily as well as hydrochlorothiazide
Study: 24648302
Drug: Bioavailability-boosted curcuminoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioavailability-boosted curcuminoids preparation (180 mg/day)
Study: 21786525
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Study: 21786525
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Study: 11999818
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion for 48 hours
Study: 11999818
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion for 48 hours plus 72 hours subcutaneous injection
Study: 8507446
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion
Study: 11999818
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of octreotide for another 72 hours
Study: 29505689
Drug: TENS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS treatment
Study: 3540813
Drug: Placebo TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TENS treatment
Study: 31331564
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus quince syrup
Study: 28371141
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy for HFrEF alone
Study: 19375592
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg daily for 6 months
Study: 15503074
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention program (six modules in five weekly group sessions)
Study: 3430263
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil therapy (M)
Study: 26585287
Drug: LY2940094 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2940094 (40 mg once daily for 8 weeks)
Study: 23767831
Drug: Aflibercept (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (administered every 2 weeks)
Study: 18832884
Drug: Recombinant native
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant native HIV-1 Tat protein vaccine
Study: 7908147
Drug: Parlodel (bromocriptine)
Normalized name: bromocriptine Oral Capsule [Parlodel]
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parlodel (bromocriptine) fast titration (15 mg/day for 3 weeks)
Study: 7908147
Drug: Parlodel (bromocriptine)
Normalized name: bromocriptine Oral Capsule [Parlodel]
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parlodel (bromocriptine) slow titration (15 mg/day for 5 weeks)
Study: 3593985
Drug: Tamoxifen (T)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (T) alone or T in combination with medroxyprogesterone acetate, diethylstilbestrol, halotestin, or aminoglutethimide
Study: 24708917
Drug: Selenium (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (60 μg/d, as Se-enriched yeast)
Study: 20555331
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg day(-1) valsartan
Study: 20555331
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg day(-1) valsartan
Study: 16759447
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) including Salvia miltiorrhiza, Acanthopanax senticosus, Ginkgo biloba, Pueraria lobata, Liguisticum chuanxiong, cow bezoar, Diospyros kaki, Gynostemma pentaphyllum
Study: 12627988
Drug: Nasal budesonide
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal budesonide 128 microg twice daily
Study: 12627988
Drug: Nasal budesonide
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal budesonide 128 microg twice daily after polypectomy
Study: 10356887
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium breve YIT4064, 50 mg daily for 28 days
Study: 2065844
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cisplatin (50 mg/m2) with short treatment regimen (6 months)
Study: 2065844
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cisplatin (50 mg/m2) with extended treatment regimen (12 months)
Study: 2065844
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cisplatin (50 mg/m2) with treatment in blocks (intervening months without cisplatin)
Study: 2065844
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cisplatin (100 mg/m2) with short treatment regimen (6 months)
Study: 2065844
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cisplatin (100 mg/m2) with extended treatment regimen (12 months)
Study: 2065844
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cisplatin (100 mg/m2) with treatment in blocks (intervening months without cisplatin)
Study: 29666026
Drug: Checkpoint inhibitors
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitors (nivolumab, pembrolizumab, cemiplimab)
Study: 27682034
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg intravenous)
Study: 22119935
Drug: levodopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa (200 mg) / benserazide (50 mg)
Study: 25231091
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg peramivir
Study: 9863850
Drug: Biofeedback‐assisted behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback‐assisted behavioral treatment
Study: 9863850
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (oxybutynin chloride, 2.5 mg daily to 5.0 mg 3 times daily)
Study: 8721904
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) for younger patients
Study: 399315
Drug: Nordial (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordial (combination of ethynyl oestradiol and levonorgestrel)
Study: 26194186
Drug: Perioperative ECF
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative ECF chemotherapy
Study: 22873758
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of botulinum toxin A (BoNT‐A) combined with standard therapy
Study: 9839623
Drug: Hyaluronidase as
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase as an additive to chemotherapy and radiation therapy
Study: 9839623
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy without hyaluronidase
Study: 7983236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of loracarbef
Study: 7983236
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dose of loracarbef
Study: 7983236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of loracarbef (women)
Study: 7983236
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dose of loracarbef (women)
Study: 7983236
Drug: loracarbef (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: loracarbef (400 mg dose)
Study: 31429629
Drug: Basic gel
Normalized name: ALCOHOL 67 mL in 100 mL TOPICAL LIQUID [Pacific Blue Basic Gel Hand Sanitizer with Moisturizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic gel containing 3%(w/w)-TTO
Study: 31429629
Drug: Advanced gel
Normalized name: Walgreens Advanced Gelatin Plus Silica 1080mg Capsule
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Advanced gel containing 3%(w/w)-TTO plus essential oils and vitamins
Study: 29560955
Drug: Early operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early operative treatment (12‐hour medication)
Study: 29560955
Drug: Long‐term conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long‐term conservative treatment (48 hours)
Study: 27075843
Drug: Weekly surveys
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly surveys
Study: 25741400
Drug: Cyanoacrylate topical
Normalized name: 2-octyl cyanoacrylate TOPICAL LIQUID (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanoacrylate topical adhesive
Study: 20942668
Drug: Tanezumab (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (10, 25, 50, 100, or 200 μg/kg)
Study: 16845627
Drug: Aventis Pasteur
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aventis Pasteur smallpox vaccine
Study: 12600796
Drug: PGE(2) (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE(2) (3, 6, and 12 nmol/ml)
Study: 12600796
Drug: ATP (9000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP (9000, 18,000, and 36,000 nmol/ml)
Study: 12600796
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bk (92 nmol), 5‐HT (156 nmol), His (140 nmol), and PGE(2) (1.95 nmol)
Study: 11672513
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + IFN (COPP: cyclophosphamide, vincristine, prednisone, procarbazine)
Study: 7989949
Drug: High-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interleukin-2 (IL-2) (720,000 IU/kg) every 8 hours
Study: 3068855
Drug: Chlorproguanil (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil (1.2 mg/kg) and dapsone (1.2 or 2.4 mg/kg)
Study: 3068855
Drug: Pyrimethamine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (1.2 mg/kg) and sulfadoxine (24 mg/kg)